Shield Blood Test Instead of a Colonoscopy

Get a colorectal screening plan you can complete. Tell a provider what has stopped you finishing a colonoscopy or stool test, and ask which screening option fits your history. If you are considering Shield instead, confirm whether an order and blood collection can be arranged before booking a draw. This comparison explains the tradeoffs behind that choice.

Care starts by chat with a licensed provider. Message us and we will confirm coverage in your state.

Choose a screening plan you can finish

Shield, FIT, Cologuard and colonoscopy are not interchangeable ways of doing the same thing. They use different samples, detect different signals, and have different abilities to identify precancerous growths. A useful comparison includes the initial test and the follow-up it may require. [1,2]

The American Cancer Society's 2026 guideline prefers stool-based tests and visual exams. It recommends blood-based testing only for people who decline or do not complete preferred options. That is the starting point for comparing Shield with those alternatives, not a small-print exception after choosing a test. [1]

If you have been putting screening off, explain what is getting in the way. The right conversation about preparation is different from the right conversation about cost, a prior bad experience, or finding someone to drive you home.

What each option actually involves

• Colonoscopy. A clinician examines the colon and rectum with a flexible scope and can biopsy tissue or remove polyps during the examination. Preparation cleans out the bowel, and sedation is commonly used. For average-risk people after a normal screening examination, the usual interval is 10 years; findings can change the plan. [2,7]
• FIT. This home stool test checks for hidden blood. It does not require bowel preparation. The ACS recommends repeating it every year when FIT is the chosen screening strategy. [3]
• Stool DNA or RNA testing. Cologuard and Cologuard Plus combine DNA testing with testing for blood in stool; ColoSense uses RNA and blood markers. These are home sample-collection options, with an ACS screening interval of three years. [3]
• Shield. This prescription blood test looks for colorectal cancer-associated signals in circulating DNA. It does not inspect or remove growths and has limited detection of precancerous lesions. [4]

A positive result from a stool or blood screening test requires colonoscopy. That means a home kit or blood draw can simplify the first step without eliminating the possibility of bowel preparation, sedation or time away for follow-up. [1,2]

Before choosing an initial test, ask who would arrange that follow-up. If your main obstacle is access to colonoscopy, it is better to name it at the start of the screening discussion than discover it after an abnormal report.

Cancer detection and prevention are different goals

Colonoscopy can remove abnormal growths. A blood test cannot. The practical importance of finding a precancerous lesion is that it may allow a clinician to remove it before cancer develops. A cancer-detection percentage alone does not capture that opportunity. [2,4]

The BLUE-C study of next-generation multitarget stool DNA testing reported 93.9% sensitivity for colorectal cancer and 43.4% for advanced precancerous lesions. FIT tested in that same study had sensitivities of 67.3% and 23.3%, respectively. The stool DNA test detected more of those findings but produced more false-positive results than FIT. [5]

In the separate ECLIPSE study, Shield's corresponding sensitivities were 83.1% for colorectal cancer and 13.2% for advanced precancerous lesions. This was not a head-to-head trial against the BLUE-C tests. Different participants and study settings limit the comparisons you can make. [6]

You also cannot compare one round of FIT with an entire repeated screening program and call the higher single-round number the winner. FIT is intended to be repeated. The FDA labeling states that Shield's superiority or noninferiority to other recommended screening methods has not been established. [3,4]

Match the obstacle to the available choices

If your concern is bowel preparation, ask about the stool-based options as well as Shield. Avoiding a colonoscopy as the first test does not automatically mean choosing blood testing. Home stool tests also avoid the initial bowel preparation, while remaining among the ACS's preferred options. [1,3]

If your concern is handling a stool sample and you will not complete a visual exam, say so plainly. That is the sort of preference the ACS's blood-test recommendation addresses. The conversation should include Shield's weaker precancer detection and your willingness to have a colonoscopy after a positive result. [1,4]

If you need a colonoscopy because of a prior finding, the decision is different. Do not cancel a surveillance examination based on a general screening comparison. Shield is not a replacement for that examination, and its labeling excludes several high-risk histories. [4]

If your concern is cost, get an estimate for the actual test and any follow-up rather than guessing from which sample seems simplest. Our insurance and cost guide provides a set of questions to use before arranging a Shield draw.

Keep the interval attached to the test

Do not borrow colonoscopy's schedule for a blood or stool test. Annual FIT and the longer interval after a normal screening colonoscopy are different screening programs. Your previous results also matter: an examination that found a polyp is not automatically the same situation as a normal average-risk screening examination. [3,7]

For blood-based tests, the ACS patient information says the optimal testing frequency is not yet clear. This is why an insurance benefit that pays at a particular interval should not be described as proof that the interval is optimal. Make the repeat-screening plan with your clinician. [3]

A short list can help you leave the discussion with a usable plan: which test you are choosing, where it happens, who receives the result, what happens if it is positive, and when the next screening discussion is due. Record the plan somewhere you can find again.

You can message Well Revolution to discuss your screening options. Include what you have already tried and what prevented completion. Read who can use Shield before treating a preference for blood collection as eligibility, and use the Shield overview for the basics of the test itself. If you settle on Shield, our guide to getting the test online in the US explains the order, the draw and the result.

What it costs with Well Revolution

$50 for a prescription. If approved, you will receive a prescription for the Shield lab order and 30 days of support. Guardant runs the test and reports the result. We are there for those 30 days to interpret it, arrange referrals, and treat if needed. Perfect for a single screening test.

Or $90 for the Unlimited Membership. If approved, you will receive 3 months of care with 7 days a week support, plus unlimited prescriptions, lab tests, imaging orders, letters and referrals with same day care, cancel anytime, no fees. Perfect for established patients looking for full care.

Getting started with Well Revolution

Care is chat-based with a licensed provider, same day, no appointment needed. Message us with what has stopped you screening so far, tell us where you are, and we will confirm coverage in your state and help you choose a test you can finish.

References

• [1] Wolf AMD et al. Colorectal cancer screening: An update to the American Cancer Society guideline, 2026. 2026.
• [2] National Cancer Institute. Screening Tests to Detect Colorectal Cancer and Polyps. accessed 2026-09-06.
• [3] American Cancer Society. Colorectal Cancer Screening Tests. 2026.
• [4] Guardant Health / FDA. Shield instructions for use and provider labeling, P230009C. 2024.
• [5] Imperiale TF et al. Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening. 2024.
• [6] Chung DC et al. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening. 2024.
• [7] US Preventive Services Task Force. Colorectal Cancer: Screening. 2021.

Reviewed by PA Michael Rubio, US Medical Director